DIAGNOS Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andre Larente
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 7005 Taschereau Boulevard Brossard QC Canada J4Z 1A7
- IPO Date
- Jun 24, 2003
- CIK
- 0001790693
- Website
- diagnos.ca
- Similar Companies
- Business
- DIAGNOS Inc. is a Canadian healthcare technology company specializing in artificial intelligence (AI)-powered software-based services for the early detection of critical eye-related health issues, primarily diabetic retinopathy. The company’s core product offering centers around CARA (Computer Assisted Retinal Analysis), a proprietary, web-based software platform that integrates fundus cameras with an advanced image processing and AI algorithm engine to assist healthcare professionals in screening for diabetic retinopathy and other retinal diseases. CARA provides detailed visualization of normal retinal landmarks and pathological changes including exudates, hemorrhages, microaneurysms, and neovascularization, supporting early diagnosis and intervention. DIAGNOS markets its services primarily to healthcare providers in Canada, the United States, Mexico, Chile, and other international markets. Founded in 1998 and headquartered in Quebec, Canada, DIAGNOS operates within the emerging technologies and healthcare sectors, focusing on software interpretation services that enhance diagnostic precision and optimize healthcare workflows through AI. Its business model revolves around delivering turnkey screening solutions and image analysis services for diabetic retinopathy, with ongoing research and development to expand its offerings to detect additional chronic disease impacts such as glaucoma. Recent major developments include a strategic partnership with Allele Capital Partners announced in May 2025, designed to refine DIAGNOS’s capital markets strategy, improve investor relations, enhance communications, and support regulatory approval efforts, including pursuing FDA clearance for its CARA system to enable expansion into the U.S. optometry market. In 2025, DIAGNOS also completed several brokered private placements raising multi-million dollar capital led by Centurion One Capital to fund growth initiatives and technological advancements. These activities illustrate the company’s strategic push to scale its operations, expand its geographic footprint, and solidify its position in the global AI-enabled healthcare screening market. Overall, DIAGNOS Inc. leverages advanced AI-driven image processing technologies to provide healthcare professionals with tools aimed at preventing vision loss due to chronic diseases by enabling early detection and intervention. Its focus on diabetic retinopathy screening, combined with strategic capital alliances and regulatory pursuits, reflects its commitment to driving digital transformation in primary care and ophthalmology sectors internationally.
Company News
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
DIAGNOS to Extend the Exercise Period of Stock Warrants
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026
DIAGNOS Announces Amendment to Convertible Debentures
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
DIAGNOS (OTCMKTS:DGNOF) Trading Up 2.6% – Time to Buy?
DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
DIAGNOS (OTCMKTS:DGNOF) Trading 1.6% Higher – Still a Buy?
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
DIAGNOS Announces the Engagement of IBN
Head to Head Analysis: DIAGNOS (OTCMKTS:DGNOF) vs. Fathom (NASDAQ:FTHM)
Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital
Contrasting DIAGNOS (OTCMKTS:DGNOF) & Priority Technology (NASDAQ:PRTH)
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
DIAGNOS Announces $2.0 Million Brokered Private Placement Led by Centurion One Capital
Comparing SAIHEAT (NASDAQ:SAIH) and DIAGNOS (OTCMKTS:DGNOF)